Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study

Journal of Hepatology

Volumn 60, Issue 2, 2014, Pages 384-391

  Morling, Joanne R ^a   Fallowfield, Jonathan A ^b   Guha, Indra N ^c   Nee, Lisa D ^d   Glancy, Stephen ^d   Williamson, Rachel M ^d   Robertson, Christine M ^a   Strachan, Mark W J ^d   Price, Jackie F ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Hepatic fibrosis; Non alcoholic fatty liver disease; Non invasive biomarker tests; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE TO ALANINE AMINOTRANSFERASE RATIO; ASPARTATE TO PLATELET RATIO INDEX; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; DIGESTIVE TRACT PARAMETERS; ECHOGRAPHY; EUROPEAN LIVER FIBROSIS PANEL; FATTY LIVER; FEMALE; FIBROSIS 4 SCORE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS MEASUREMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOCYTE COUNT;

AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; SCOTLAND;

EID: 84892527975     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.10.017     Document Type: Article

References (40)

1. J.D. Browning, L.S. Szczepaniak, R. Dobbins, P. Nuremberg, J.D. Horton, and J.C. Cohen et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 2004 1387 1395
2. R.M. Williamson, J.F. Price, S. Glancy, E. Perry, L.D. Nee, and P.C. Hayes et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study Diabetes Care 34 2011 1139 1144
3. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 2002 1221 1231
4. G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari, and L. Zenari et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients Diabetes Care 30 2007 1212 1218
5. A.A. Bravo, S.G. Sheth, and S. Chopra Liver biopsy N Engl J Med 344 2001 495 500
6. R. Vuppalanchi, A. Unalp, M.L. Van Natta, O.W. Cummings, K.E. Sandrasegaran, and T. Hameed et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 7 2009 481 486
7. V. Ratziu, F. Charlotte, A. Heurtier, S. Gombert, P. Giral, and E. Bruckert et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease Gastroenterology 128 2005 1898 1906
8. R.B. Merriman, L.D. Ferrell, M.G. Patti, S.R. Weston, M.S. Pabst, and B.E. Aouizerat et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease Hepatology 44 2006 874 880
9. I.T. Gilmore, A. Burroughs, I.M. Murray-Lyon, R. Williams, D. Jenkins, and A. Hopkins Indications, methods, and outcomes of percutaneous liver biopsy in England and wales: an audit by the British Society of Gastroenterology and the royal college of physicians of London Gut 36 1995 437 441
10. S.A. Padia, M.E. Baker, C.J. Schaeffer, E.M. Remer, N.A. Obuchowski, and C. Winans et al. Safety and efficacy of sonographic-guided random real-time core needle biopsy of the liver J Clin Ultrasound 37 2009 138 143
11. R.P. Myers, A. Fong, and A.A.M. Shaheen Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies Liver Int 28 2008 705 712
12. F. Piccinino, E. Sagnelli, G. Pasquale, G. Giusti, A. Battocchia, and M. Bernardi et al. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68 276 biopsies J Hepatol 2 1986 165 173
13. M. Prashanth, H.K. Ganesh, M.V. Vima, M. John, T. Bandgar, and S.R. Joshi et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus J Assoc Physicians India 57 2009 205 210 [see comment]
14. P. Gupte, D. Amarapurkar, S. Agal, R. Baijal, P. Kulshrestha, and S. Pramanik et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus J Gastroenterol Hepatol 19 2004 854 858
15. N.C. Leite, C.A. Villela-Nogueira, V.L.N. Pannain, A.C. Bottino, G.F.M. Rezende, and C.R.L. Cardoso et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors Liver Int 31 2011 700 706
16. M.J. Armstrong, D.D. Houlihan, L. Bentham, J.C. Shaw, R. Cramb, and S. Olliff et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort J Hepatol 56 2012 234 240
17. D. Roulot, J.-L. Costes, J.-F. Buyck, U. Warzocha, N. Gambier, and S. Czernichow et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years Gut 60 2011 977 984
18. R.M. Williamson, J.F. Price, P.C. Hayes, S. Glancy, B.M. Frier, and G.I. Johnston et al. Prevalence and markers of advanced liver disease in type 2 diabetes QJM 105 2012 425 432
19. J. Price, R. Reynolds, R. Mitchell, R. Williamson, F.G. Fowkes, and I. Deary et al. The Edinburgh type 2 diabetes study: study protocol BMC Endocr Disord 8 2008 18
20. R.E. Marioni, M.W.J. Strachan, R.M. Reynolds, G.D.O. Lowe, R.J. Mitchell, and F.G.R. Fowkes et al. Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh type 2 diabetes study Diabetes 59 2010 710 713
21. R.M. Williamson, E. Perry, S. Glancy, I. Marshall, C. Gray, and L.D. Nee et al. The use of ultrasound to diagnose hepatic steatosis in type 2 diabetes: intra- and interobserver variability and comparison with magnetic resonance spectroscopy Clin Radiol 66 2011 434 439
22. C.-T. Wai, J.K. Greenson, R.J. Fontana, J.D. Kalbfleisch, J.A. Marrero, and H.S. Conjeevaram et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology 38 2003 518 526
23. I.N. Guha, J. Parkes, P. Roderick, D. Chattopadhyay, R. Cross, and S. Harris et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers Hepatology 47 2008 455 460 [see comment]
24. A. Vallet-Pichard, V. Mallet, B. Nalpas, V. Verkarre, A. Nalpas, and V. Dhalluin-Venier et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest Hepatology 46 2007 32 36
25. Royal College of Physicians. Inquiry on alcohol guideliines. London, UK; 2011
26. N. Chalasani, Z. Younossi, J.E. Lavine, A.M. Diehl, E.M. Brunt, and K. Cusi et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 55 2012 2005 2023
27. F. Alvarez, P.A. Berg, F.B. Bianchi, L. Bianchi, A.K. Burroughs, and E.L. Cancado et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis J Hepatol 31 1999 929 938
28. S. McPherson, S.F. Stewart, E. Henderson, A.D. Burt, and C.P. Day Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease Gut 59 2010 1265 1269
29. V.W.-S. Wong, J. Vergniol, G.L.-H. Wong, J. Foucher, H.L.-Y. Chan, and B. Le Bail et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease Hepatology 51 2010 454 462
30. A.R. Feinstein, and D.V. Cicchetti High agreement but low kappa: I. The problems of two paradoxes J Clin Epidemiol 43 1990 543 549
31. D.V. Cicchetti, and A.R. Feinstein High agreement but low kappa: II. Resolving the paradoxes J Clin Epidemiol 43 1990 551 558
32. G. Marchesini, M. Brizi, A.M. Morselli-Labate, G. Bianchi, E. Bugianesi, and A.J. McCullough et al. Association of nonalcoholic fatty liver disease with insulin resistance Am J Med 107 1999 450 455
33. E. Bugianesi, E. Gentilcore, R. Manini, S. Natale, E. Vanni, and N. Villanova et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease Am J Gastroenterol 100 2005 1082 1090
34. F. Zhang, D. Kong, Y. Lu, and S. Zheng Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside Cell Mol Life Sci 70 2013 259 276
35. P. Ray, Y.L. Manach, B. Riou, and T.T. Houle Statistical evaluation of a biomarker Anesthesiology 112 2010 1023 1040 10.1097/ALN.1020b1013e3181d47604
36. R.P. Myers, G. Pomier-Layrargues, R. Kirsch, A. Pollett, A. Duarte-Rojo, and D. Wong et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients Hepatology 55 2012 199 208
37. J.M. Bland, and D.G. Altman Statistics notes: cronbach's alpha BMJ 314 1997 572
38. G. Siest, F. Schiele, M.-M. Galteau, E. Panek, J. Steinmetz, and F. Fagnani et al. Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values Clin Chem 21 1975 1077 1087
39. D. Prati, E. Taioli, A. Zanella, E.D. Torre, S. Butelli, and E. Del Vecchio et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels Ann Intern Med 137 2002 1 10
40. M. Yin, J.A. Talwalkar, K.J. Glaser, A. Manduca, R.C. Grimm, and P.J. Rossman et al. Assessment of hepatic fibrosis with magnetic resonance elastography Clin Gastroenterol Hepatol 5 2007 e1202